Clinical Trial Update: Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating belumosudil to prevent chronic lung allograft dysfunction in high-risk lung transplant recipients and is currently recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Allograft Dysfunction

Drugs mentioned

• Belumosudil (belumosudil)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Lung Transplant | Phase 2 | Status: RECRUITING